Beyond Xeljanz: An Inflammation & Immunology Portfolio Blooms At Pfizer

Xeljanz’s launch in rheumatoid arthritis has gotten off to a slower than expected start, highlighting the challenges for new drugs in competitive inflammatory diseases. But Pfizer is digging in its heels and hoping that pipeline drugs, including next-generation JAKs, will stand out by addressing unmet medical need in indications like lupus, type1 diabetes and inflammatory bowel disease.